Rosuvastatin versus Atorvastatin zur Sekundärprävention bei kardiovaskulären RisikopatientenRosuvastatin versus atorvastatin for secondary prevention in cardiovascular risk patients

被引：0

作者：

Moritz Schanz ^{[1
]}

Jörg Latus ^{[1
]}

机构：

[1] Robert-Bosch-Krankenhaus Stuttgart,Abteilung für Allgemeine Innere Medizin und Nephrologie

来源：

Die Nephrologie | 2024年 / 19卷 / 6期

关键词：

D O I：

10.1007/s11560-024-00789-0

中图分类号：

学科分类号：

摘要：

引用

页码：370 / 372

页数：2

共 50 条

[31] Efficacy and safety of rosuvastatin versus atorvastatin in high-risk Chinese patients with hypercholesterolemia: a randomized, double-blind, active-controlled study
Zhao, Shuiping
Peng, Daoquan
CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (02) : 227 - 235
[32] Cost-effectiveness of intensive lipid-lowering treatment with atorvastatin 80mg versus 10mg in secondary cardiovascular prevention in the UK
Taylor, D. C. A.
Pandya, A.
Thompson, D.
Chu, P.
Graff, J.
Drummond, M.
Larosa, J. C.
Grundy, S. M.
Shepherd, J.
Wenger, N. K.
ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 121 - 121
[33] CARDIOVASCULAR RISK FACTOR MANAGEMENT: SINGLE-PILL AMLODIPINE/ATORVASTATIN VERSUS USUAL CARE IN PATIENTS WITH HYPERTENSION AND ADDITIONAL RISK FACTORS - THE CRUCIAL TRIAL
Lopez, A. Pavia
Erdine, S.
Zamorano, J.
Kim, J. H.
Al Khadra, A.
Westergaard, M.
Sutradhar, S.
Yunis, C.
JOURNAL OF HYPERTENSION, 2010, 28 : E278 - E279
[34] Atorvastatin Reduces the Risk of Cardiovascular Events in Patients With Carotid Atherosclerosis A Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial
Sillesen, Henrik
Amarenco, Pierre
Hennerici, Michael G.
Callahan, Alfred
Goldstein, Larry B.
Zivin, Justin
Messig, Michael
Wclch, K. Michacl
STROKE, 2008, 39 (12) : 3297 - 3302
[35] Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: A randomized, open-label, parallel-group, multicenter study (DISCOVERY alpha study)
Binbrek, AS
Elis, A
Al-Zaibag, M
Eha, J
Keber, I
Cuevas, AM
Mukherjee, S
Miller, TR
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2006, 67 (01): : 21 - 43
[36] Population effect of extended-release niacin/lovastatin versus atorvastatin in patients with hypertension and multiple lipid abnormalities at high risk for cardiovascular events
Charland, Scott L.
Quimbo, Ralph
Cziraky, Mark J.
Stanek, Eric J.
CIRCULATION, 2007, 115 (08) : E257 - E258
[37] Cost-effectiveness of Atorvastatin plus Amlodipine versus Atorvastatin plus Atenolol in hypertensive patients without previous coronary heart disease, normal to mildly elevated cholesterol levels and at least 3 cardiovascular risk factors
F Bobadilla, J.
Merikle, E.
Garcia, M.
Darba, J.
Sanchez, C.
VALUE IN HEALTH, 2007, 10 (06) : A415 - A416
[38] Calculation of individual cardiovascular risk in a primary prevention setting shows a high number of patients with a high risk scoreIm Kontext einer Primärprävention findet sich bei einer großen Anzahl von Patienten ein hoher Score für ein kardiovaskuläres Ereignis
M. Neuss
M. Roser
S. Kelle
F. Girke
G. Winbeck
P. Stawowy
E. Fleck
Zeitschrift für Kardiologie, 2004, 93 (5): : 413 - 415
[39] Lipidprofil und Therapiestatus in der Sekundärprävention bei Hochrisiko-Patienten mit klinisch manifester Arteriosklerose und/oder Diabetes mellitus: Das Hospital Screening Projekt (HSP) in ÖsterreichLipid profiles and therapy status in the secondary prevention of high risk patients with cardiovascular disease and/or diabetes mellitus: The Austrian Hospital Screening Project (HSP)
Michael Roden
Kurt Huber
Wiener klinische Wochenschrift, 2008, 120 : 558 - 565
[40] A Comparison of Switching to Ezetimibe/Simvastatin (10 mg/20 mg) versus Doubling the Statin Dose to Simvastatin 40 mg or Atorvastatin 20 mg or Switching to Rosuvastatin 10 mg in Patients with Cardiovascular Disease and Diabetes Mellitus
Rosen, Jeffrey B.
Jimenez, Jose G.
Pirags, Valdis
Vides, Hella
Hanson, Mary E.
Massaad, Rachid
McPeters, Gail
Triscari, Joseph
Brudi, Philippe
CIRCULATION, 2011, 124 (21)

← 1 2 3 4 5 →